C-peptide, Na+,K+-ATPase, and Diabetes
2004

C-peptide and Na+,K+-ATPase in Diabetes

publication 10 minutes Evidence: moderate

Author Information

Author(s): P. Vague, T. C. Coste, M. F. Jannot, D. Raccah, M. Tsimaratos

Primary Institution: Departement de Nutrition-Endocrinologie-Maladies Metaboliques, Marseille, France

Hypothesis

The study investigates the relationship between C-peptide levels and Na+,K+-ATPase activity in diabetic patients.

Conclusion

C-peptide administration can restore Na+,K+-ATPase activity in diabetic patients, which may help prevent complications associated with diabetes.

Supporting Evidence

  • C-peptide infusion restores Na+,K+-ATPase activity in type 1 diabetic patients.
  • Low Na+,K+-ATPase activity is associated with diabetic complications.
  • C-peptide levels correlate with Na+,K+-ATPase activity in type 2 diabetic patients.
  • Short-term C-peptide infusion improves erythrocyte Na+,K+-ATPase activity.
  • Diabetic patients with low C-peptide levels show decreased enzyme activity.

Takeaway

C-peptide helps a special enzyme work better in people with diabetes, which can make them feel healthier.

Methodology

The study involved both in vivo and in vitro experiments to assess the effects of C-peptide on Na+,K+-ATPase activity in diabetic patients and animal models.

Potential Biases

Potential biases may arise from the selection of participants and the methods used to measure enzyme activity.

Limitations

The study primarily focuses on specific populations and may not be generalizable to all diabetic patients.

Participant Demographics

The study includes type 1 and type 2 diabetic patients, with a focus on those with varying levels of C-peptide.

Statistical Information

P-Value

0.002

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1080/15438600490424514

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication